Showing results (401-410 of 566) with videos related to

Sort By:
Pageof 57
Journal of Clinical Epidemiology|March 4, 2014
Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0Maarten Boers, John R Kirwan, George Wells, et al.
The Journal of Rheumatology|July 17, 2020
Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal StudiesUta Kiltz, James Cheng-Chung Wei, Désirée van der Heijde, et al.
Lupus Science & Medicine|January 24, 2025
Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS)Martin Aringer, Laurent Arnaud, Richard A Furie, et al.
The Journal of Rheumatology|August 13, 2009
Multiple computer-based methods of measuring joint space width can discriminate between treatment arms in the COBRA trial -- Update of an ongoing OMERACT projectJohn T Sharp, Jane Angwin, Maarten Boers, et al.
JAMA Dermatology|January 24, 2024
Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis: A Systematic ReviewLourdes M Pérez-Chada, Zachary H Hopkins, Deepak M W Balak, et al.
Arthritis Care & Research|March 23, 2012
Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-associated uveitis: a consensus effort from the multinational interdisciplinary working group for uveitis in childhoodArnd Heiligenhaus, Ivan Foeldvari, Clive Edelsten, et al.
The Journal of Rheumatology|April 16, 2021
Test-retest Reliability for HAQ-DI and SF-36 PF for the Measurement of Physical Function in Psoriatic ArthritisYing Ying Leung, William Tillett, Pil Hojgaard, et al.
Rheumatology (Oxford, England)|September 1, 2020
Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritisLaura C Coates, Joseph F Merola, Philip J Mease, et al.
Clinical and Experimental Rheumatology|May 10, 2016
Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trialsGene V Wallenstein, Keith S Kanik, Bethanie Wilkinson, et al.
Arthritis Research & Therapy|July 27, 2020
Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviewsRikke A Andreasen, Lars E Kristensen, Xenofon Baraliakos, et al.
Pageof 57